Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 588

1.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.

PMID:
31200358
2.

Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma.

Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM.

Blood. 2019 Jun 11. pii: blood.2019001272. doi: 10.1182/blood.2019001272. [Epub ahead of print]

PMID:
31186274
3.

Multiple neurosteroid and cholesterol binding sites in voltage-dependent anion channel-1 determined by photo-affinity labeling.

Cheng WWL, Budelier MM, Sugasawa Y, Bergdoll L, Queralt-Martín M, Rosencrans W, Rostovtseva TK, Chen ZW, Abramson J, Krishnan K, Covey DF, Whitelegge JP, Evers AS.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun 5. pii: S1388-1981(19)30096-4. doi: 10.1016/j.bbalip.2019.06.004. [Epub ahead of print]

PMID:
31176038
4.

Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.

Abramson JS, Lunning M, Palomba ML.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:446-453. doi: 10.1200/EDBK_238693. Epub 2019 May 17.

PMID:
31099671
5.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.

Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS.

Leuk Lymphoma. 2019 May 10:1-8. doi: 10.1080/10428194.2019.1608533. [Epub ahead of print]

PMID:
31074316
6.

Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response.

Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, Beigi RH, Cravioto AR, Durbin AP, Gellin BG, Gupta SB, Kaslow DC, Kochhar S, Luna F, Saenz C, Sheffield JS, Tindana PO; PREVENT Working Group.

Vaccine. 2019 May 3. pii: S0264-410X(19)30045-3. doi: 10.1016/j.vaccine.2019.01.011. [Epub ahead of print] Review.

7.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

8.

Rbpj expression in regulatory T cells is critical for restraining TH2 responses.

Delacher M, Schmidl C, Herzig Y, Breloer M, Hartmann W, Brunk F, Kägebein D, Träger U, Hofer AC, Bittner S, Weichenhan D, Imbusch CD, Hotz-Wagenblatt A, Hielscher T, Breiling A, Federico G, Gröne HJ, Schmid RM, Rehli M, Abramson J, Feuerer M.

Nat Commun. 2019 Apr 8;10(1):1621. doi: 10.1038/s41467-019-09276-w.

9.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP.

J Clin Oncol. 2019 Apr 2:JCO1801994. doi: 10.1200/JCO.18.01994. [Epub ahead of print]

PMID:
30939090
10.

Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial.

Rahbari-Oskoui FF, Abramson JL, Bruckman AM, Chapman AB, Cotsonis GA, Johnson SA, Bliwise DL.

Complement Ther Med. 2019 Apr;43:157-164. doi: 10.1016/j.ctim.2019.01.026. Epub 2019 Jan 31.

PMID:
30935524
11.

Tuft cells: From the mucosa to the thymus.

Nevo S, Kadouri N, Abramson J.

Immunol Lett. 2019 Jun;210:1-9. doi: 10.1016/j.imlet.2019.02.003. Epub 2019 Mar 21. Review.

PMID:
30904566
12.

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.

Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J.

Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.

PMID:
30808634
13.

Reply.

Fung THM, Ojha S, Abramson J, Holden R.

Ophthalmology. 2019 Mar;126(3):e20-e21. doi: 10.1016/j.ophtha.2018.10.025. No abstract available.

PMID:
30803525
14.

Selective inhibition of the FcεRI-induced de novo synthesis of mediators by an inhibitory receptor.

Abramson J, Licht A, Pecht I.

EMBO J. 2019 Feb 1;38(3). pii: e101419. doi: 10.15252/embj.2018101419. No abstract available.

15.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jan;17(1):12-20. doi: 10.6004/jnccn.2019.0002.

PMID:
30659125
16.

Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.

Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM.

Blood. 2019 Mar 21;133(12):1313-1324. doi: 10.1182/blood-2018-09-871418. Epub 2019 Jan 7.

17.

Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.

Qualls D, Abramson JS.

Haematologica. 2019 Jan;104(1):25-34. doi: 10.3324/haematol.2018.195834. Epub 2018 Dec 20. Review.

18.

Design and clinical validation of a point-of-care device for the diagnosis of lymphoma via contrast-enhanced microholography and machine learning.

Im H, Pathania D, McFarland PJ, Sohani AR, Degani I, Allen M, Coble B, Kilcoyne A, Hong S, Rohrer L, Abramson JS, Dryden-Peterson S, Fexon L, Pivovarov M, Chabner B, Lee H, Castro CM, Weissleder R.

Nat Biomed Eng. 2018 Sep;2(9):666-674. doi: 10.1038/s41551-018-0265-3. Epub 2018 Jul 23.

19.

Global Funders Consortium for Universal Influenza Vaccine Development.

Bresee JS, McKinlay MA, Abramson J, Klugman KP, Wairagkar N; Global Funders Consortium for Universal Influenza Vaccine Development.

Vaccine. 2019 Jan 7;37(2):211-213. doi: 10.1016/j.vaccine.2018.11.037. Epub 2018 Nov 30. No abstract available.

PMID:
30503660
20.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868

Supplemental Content

Loading ...
Support Center